Novo Nordisk Foundation CEO surprised by mRNA Nobel Prize snub

The social significance of the mRNA-based Covid-19 vaccines is obvious, says Mads Krogsgaard Thomsen, who suggests that the technology may not have won because the committee did not manage to evaluate the vaccines in time.

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen | Photo: Jacob Ehrbahn/Politiken

The CEO of the Novo Nordisk Foundation, Mads Krogsgaard Thomsen, believes that David Julius and Ardem Patapoutian only won the Nobel Prize for medicine because the committee did not have time to properly evaluate the research behind the mRNA-based Covid-19 vaccines.

He does acknowledge that the winners have done an important bit of work within pain receptor research – Julius used capsaicin from peppers to research the nervous system, while Patapoutian has worked with touch sensors – but believes that the social consequences of the vaccines are more significant.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs